What's in Mallinckrodt Pharmaceuticals's pipeline?

Mallinckrodt Pharmaceuticals has 21 drugs in our index: 9 marketed, 0 filed, 8 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Mallinckrodt Pharmaceuticals's portfolio?

Top competitors by shared drug class: , The University of Texas Health Science Center, Houston, Chang Gung Memorial Hospital, AbbVie (prior sponsor, Abbott), Ain Shams University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mallinckrodt.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Mallinckrodt Pharmaceuticals — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mallinckrodt Pharmaceuticals (MNK) pipeline: 9 marketed, 0 filed, 8 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

MNK (NYSE) 9 marketed 0 filed 8 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cholebrine	IOCETAMIC ACID	marketed	iocetamic acid		Other	1982-01-01
Cyanocobalamin Co 57	cyanocobalamin (57Co)	marketed	Radioactive Diagnostic Agent	Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial, Methionine synthase, Methionine synthase reductase	Hematology	1968-01-01
Phosphotope	sodium phosphate (32P)	marketed			Hematology	1959-01-01
IV Acetaminophen	IV Acetaminophen	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes	Pain Management
Restoril	temazepam	marketed	Benzodiazepine [EPC]	Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2	Neuroscience
Xe 133	xenon (133Xe) gas	marketed	Inhalation Diagnostic Agent [EPC]		Respiratory
Oxycodone hydrochloride tablet 15 mg	Oxycodone hydrochloride tablet 15 mg	marketed
Repository Corticotropin Injection	Repository Corticotropin Injection	marketed
IV Acetaminophen (Treatment A)	IV Acetaminophen (Treatment A)	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes	Pain Management
Nitric Oxide plus Oxygen	Nitric Oxide plus Oxygen	phase 3	Inhaled vasodilator	Soluble guanylate cyclase / cGMP pathway	Cardiovascular / Pulmonary
COV155	COV155	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)	Neurology / Psychiatry
IV Control	IV Control	phase 3			Critical Care

Therapeutic area mix

Hematology · 3
Other · 3
Pain Management · 2
Neurology / Psychiatry · 1
Neuroscience · 1
Respiratory · 1
Rheumatology / Pain Management · 1
Cardiovascular / Pulmonary · 1
Surgery/Hemostasis · 1
Critical Care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 3 shared drug classes
The University of Texas Health Science Center, Houston · 2 shared drug classes
Chang Gung Memorial Hospital · 2 shared drug classes
AbbVie (prior sponsor, Abbott) · 1 shared drug class
Ain Shams University · 1 shared drug class
Albina Nowak, MD · 1 shared drug class
Abliva AB · 1 shared drug class
Alfasigma S.p.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mallinckrodt Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Mallinckrodt Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mallinckrodt. Accessed 2026-06-10.